



Cloudr Group Limited

智雲健康科技集團*

(Incorporated in the Cayman Islands with limited liability)

Stock Code : 9955

Environmental,
Social and
Governance Report
2022



* For identification purpose only

Contents

- 1. ABOUT THE REPORT 3
- 2. STATEMENT OF THE BOARD..... 4
- 3. CHAIRMAN'S MESSAGE 5
- 4. HONORS AND AWARDS 6
- 5. ENVIRONMENTAL ASPECT 7
- 6. SOCIAL ASPECT..... 10
- 7. GOVERNANCE ASPECT..... 28
- 8. APPENDIX: CONTENT INDEX FOR REPORTING GUIDE..... 38



1. ABOUT THE REPORT

PRESENTATION OF THE REPORT

This Environmental, Social and Governance (hereinafter referred to as “**ESG**”) report is presented electronically in both Traditional Chinese and English.

CURRENCY

Unless specified, the monetary amounts are presented in Renminbi (RMB) in this report.

REPORTING SCOPE

The aim of this report is to provide information regarding the ESG-related performance of ClouDr Group Limited (the “**Company**”, together with its subsidiaries and consolidated affiliated entities, the “**Group**”, “**ClouDr**” or “**we**”) from 1 January, 2022 to December 31, 2022 (“**Reporting Period**”). In determining the components included in the Report, the Group’s senior management has considered the extent of different business activities’ impact on the Group’s policy, financial, environmental and social performance.

SOURCE OF INFORMATION

The information and data conferred in this report primarily derive from the Company’s database, internal statistical reports, and public information, including annual reports of the Company and media releases.

REFERENCE AND PRINCIPLES

This report references the United Nations Sustainable Development Goals (UN SDGs) and the ESG Reporting Guide set out in Appendix 27 to the Listing Rule of The Stock Exchange of Hong Kong Limited (the “**Hong Kong Stock Exchange**”). The four disclosure principles of materiality, quantitative, balance, and consistency are also considered in this report.

Materiality: The Board and the senior management reviewed and confirmed the material ESG issues, and the identified material issues were used as the focus for the preparation of this Report.

Quantitative: This Report describes the criteria and methods for calculating the relevant data, as well as the associated assumptions. Key performance indicators (“**KPI(s)**”) are provided to establish benchmarks where practicable.

Consistency: this is the first ESG disclosure by the Group after the HKEX listing on July 2022. Unless otherwise specified, the Group will continue to use the same disclosure and statistical methodology going forward.

CONTACT THE GROUP

The Group is committed to fulfilling social responsibility, promoting employee benefits and development, protecting the environment and giving back to the community and achieving sustainable growth. The Group welcomes comments from stakeholders on our environmental, social and governance policies and performance. Our ESG report can be accessed on www.cloudr.cn, and relevant comments may be sent by email to cloudrir@91jkys.com.

2. STATEMENT OF THE BOARD

The board of directors (the “**Board**”) is responsible for evaluating the Group’s environmental, social and governance risks, and ensuring that necessary internal control and risk management frameworks are in place and operating efficiently. The Board is dedicated to incorporating environmental and social aspects into its daily operations and believes that environmental, social, and governance risks are essential to the effective operation of the Group. In order for us to continuously create value for our stakeholders, the Group’s corporate governance is essential for ensuring that the ESG topic of the Group is well-considered and incorporated into the business agenda. As the Group’s highest governance body, the Board sets the direction of our business strategy as well as the management of our business activities, along with a well-established governance structure in place to govern our corporate behavior. The Board is ultimately in charge of ensuring that the internal control system and ESG risk management are effective.

The Board advises management to regularly assess the key risks and uncertainties the Group faces, participates in the development of risk management strategies, and continuously evaluates the suitability of pertinent risk assessments and strategies. The Board also regularly evaluates the system’s operational effectiveness and whether it includes crucial control measures for significant ESG issues. The Group has designated specific staff members to be in charge of gathering all pertinent data for each aspect of the ESG report and preparing it with the assistance of outside experts. Each department provides the Board with regular updates, helps identify and assess risks, such as supply chain management, hazardous wastes from the near-validity drugs, which are related to the Group’s businesses, and evaluates the efficiency and suitability of internal control mechanisms. Aside from looking at labor practices, environmental, health and safety, and other environmental, social, and governance issues, assigned employees will also assess the Group’s performance.

3. CHAIRMAN'S MESSAGE



In light of COVID-19 prevention and control efforts from 2020 to 2022, the public health system and digital transformation have become increasingly important in people's lives and the healthcare industry development. Chinese government has emphasized that people's health is a key indicator of a prosperous nation and must give strategic priority to ensuring the people's health and improve policies on promoting public health.

As a leading company in digital chronic disease management, ClouDr have leveraged our unique competencies to actively contribute to epidemic prevention and control, and provide healthcare services to the public and helped build the health industry through the provision of our SaaS services, internet hospital and medical and health product supply.

The idea of sustainable development based on the "environmental, social, and governance" three dimensions has received growing attention in many sectors. The Hong Kong Stock Exchange furthermore has put strong effort on promoting the concept and set a new standard for listed companies' ESG management and disclosure. We recognize the importance of Environmental, Social, and Governance practices in creating long-term value and believe that by prioritizing sustainability and social responsibility, we can further optimize our operation, mitigate potential risks and improve employee engagement. We believe that by integrating ESG considerations into our daily operations and governance, we can create a more sustainable and equitable future for all stakeholders, including our customers, suppliers, employees, investors, and the broader community.

During 2022, for environmental aspects, we have encouraged serials of measures such as working from home to reduce commuting and virtual conferencing to reduce the need for travel especially during the peak period of epidemic outbreak. Our internet hospital has issued more than 170mm online prescriptions which not only help millions of people acquire medical services but also save energy and resources from issuing paper prescriptions and patients commuting to hospitals. Our SaaS systems also help reduce paper usage from our customers by digitalizing their working process and documentation.

For social aspects, we value our employees and are committed to providing a safe and inclusive workplace. We also provided additional training for our employees to ensure that they have the necessary skills and knowledge to perform their jobs safely and effectively. In response to the COVID-19 pandemic, we have implemented measures to protect the health and safety of our employees. We have provided our employees with personal protective equipment, medicines, food and daily necessities during those challenging time. We have implemented serials of policies and procedures to ensure that we are conducting our business in a manner that we are responsible for our product and our suppliers are aligned with our governance criterions. We are also committed to giving back to our communities. For instance, we offered multiple rounds of free online healthcare services and joined hands with hospitals and pharmacies across the country to extend high-quality medical and health services to the "last mile"; we donated medical products to certain communities and facilitated government on epidemic prevention and control through our service capabilities.

Moving forward, we will continue to work towards our mission of chronic disease management and digitalization of healthcare services while integrating ESG principles. With the rising demand for and value of chronic disease management and digitalization of the healthcare industry, we will remain committed to the long-term development of medical and health services in the country. We will continue to work towards our ESG goals in the coming years and make a positive impact on the world around us.

Ming Kuang

Chairman of the Board



4. HONORS AND AWARDS

April 2022

The “AI Remote Prescription Management Lens” was selected as an Excellent Case of Artificial Intelligence Innovation and Development in 2021

May 2022

The Company was awarded the “Most Influential Enterprise in Medical and Healthcare” in the 2021 China Medical and Healthcare Industry Investment and Financing Honour List

June 2022

The Company was selected as the “2022 Future Healthcare VB 100 — TOP 100 Digital Health Companies”

July 2022

The Company was awarded “Top 100 Public Welfare Technology Enterprises in Yuhang District”

The “AI-based SaaS consultation system for urban smart pharmacies” was selected as a demonstration case of Beijing National Artificial Intelligence Innovation Application Pilot Zone

August 2022

The Company was awarded the “2022 Hangzhou Artificial Intelligence Major Science and Technology Innovation Project Plan”

November 2022

The Company was awarded the “T+ Employer™”

December 2022

A series of annual honors and awards including below:

The Company was awarded the “Strongest Potential IPO of the Year” by GURUCLUB

The Company was awarded the “High-quality Development Listed Company Award” by Time Finance

The Company was awarded the “Medical and Healthcare Consumer Enterprise of the Year” by TMTPOST

The Company was awarded the “2022 Listed Companies Most Concerned by Investors” by HSTONG

The Company was awarded the “2022 Optimal Solution — Golden Ruyi Award” by CN-Healthcare

The Company was awarded “Quality Technology Service Provider” for 2022 Excellent Case of Digital Intelligence Transformation and Innovation Practice by CYZONE

The Company was awarded “2022 China TOP10 Innovative Listed Companies in Great Health Industry” by Iyiu Health

The Company was awarded the “Bio-Pharma Industry Excellence Award” by JRJ.com



5. ENVIRONMENTAL ASPECT

Overview

We adhere to laws and regulations such as the “Environmental Protection Law of the PRC,” “Law of the PRC on Energy Conservation,” and “Good Supplying Practice” and formed our ESG Policy to manage potential ESG risks related to air and greenhouse gas emissions, discharges into water and land, generation of waste and climate-related issues. We support green operations and encourage carbon reduction behaviors among our employees and leadership team. Our online medical services and electric prescriptions help the whole nation to realize massive savings from carbon emissions and paper usages. We manage medical wastes with the utmost care and work to establish an environmentally friendly company.

Our ESG Policy requests our board, management team and Government Affairs department actively follow the laws, regulations, guidances, industry best-practice updates about ESG management and environment and nature resource and climate-related issues to identify potential significant impact on our business operation and build mitigation plans. To our best knowledge, there was no material non-compliance with relevant laws and regulations relating to air and greenhouse gas emissions, discharges into water and land, generation of hazardous and non-hazardous wastes, nor have we identified any material climate-related issues. The resource used by the Group were mainly electricity and water. Given the Group’s business nature, the Group believes that the impact directly exerted by its business operation on the environment and natural resources and climate was insignificant at this moment. In addition, following guidance from our ESG Policy, our management team will review and evaluate risks and impacts related to the environment and natural resources and climate-related issues on a yearly basis.

In 2022, our total electricity consumption was 457.19 megawatt hour (MWh), which was 0.34 MWh per employee. We aim to increase our energy use efficiency by reducing electricity consumption per employee by 5% in 5 years through more training, more reminders to our employees and adopting office energy-saving measures such as expanding the use of LED energy-saving lights and reducing air conditioner utilisation. The water resources used by the Group for operation mainly come from municipal running water supply and we have no issue in sourcing water that is fit for the purpose. Because our offices are rental and water resources are provided in shared public areas, we have no statistical data on water consumption and we are unable to set water efficiency targets.

In 2022, the total packaging material we used for products delivery was approximately 60 tons, which was on average equivalent to 15g per package. We aim to reduce 5% of the packaging material per package by exploring more effective package approach and packaging materials which are more environmental friendly.

Green operation

We are committed to sustainability as part of our corporate strategy, and we strive to cultivate a sustainable mindset among our employees and work environment. We have conducted a series of campaigns that aim to reduce waste and carbon emissions of both our Company and our employees, including trash-sorting in all of our offices, water reduction, and carbon emission reduction.

We are also committed to carbon mitigation measures and will continue to explore ways to further improve energy efficiency. In our offices, we have internal policies for when and how air conditioners are to be used, based on temperature and time.



5. ENVIRONMENTAL ASPECT

Our ESG Policy encouraged a series of measures to promote environmental-friendly operations in our offices and daily operations. Below are some of the examples:

- We ask our employees to be mindful of the environment when consuming office supplies, such as using double-sided or multiple pages printing and only printing when necessary or re-use paper where practicable;
- We use OA system to digitalize the most of business review processes and internal control processes to promote a paperless office environment and reduce paper consumption;
- In order to maximize office efficiency and minimize energy waste, we use leased offices to maximize office utilization by sharing workspaces for multiple functional teams, advocate for an open office environment and set no separate office even for most of our senior management team;
- During the peak period of the epidemic outbreak, we encouraged our employees to work from home to reduce transportation commuting and used virtual conferencing to reduce travel;
- We strictly implement the standard of 26°C for air conditioning in summer and 22°C in winter to reduce energy consumption;
- We encourage our employees to commute green by taking more public transportation such as subway;
- We do not allow employees to use high-power electrical appliances such as heaters and hot water kettles in the office;
- We request employees to turn off display in a timely manner when leaving the workstation and the lighting and air conditioning should be turned off when leaving office or meeting room;
- We sort daily operation wastes in accordance with local regulations and then hand over to a qualified third-party company for disposal; and
- We have established several protocols in our offices in effort to reduce water-usage. For example, we have administrative staff regularly check status of water supply facilities to ensure no water waste and we placed signs to remind our employees to reduce their water usage.

In 2022, our carbon dioxide equivalent was approximately 261 ton, which was 0.19 ton per employee (Note: Our emission is mainly indirect energy emissions (category 2) caused by outsourced electricity. We do not generate significant direct greenhouse gas emissions because we do not operate manufacturing sites and we only use electricity for office daily operational uses. The calculation is checked according to the ESG Guide of Hong Kong Stock Exchange and the Guidelines for Accounting Method and Reporting of Greenhouse Gas Emission from Enterprises issued by the Ministry of Ecology and Environment of the People's Republic of China).

In terms of the target setting, we aim to reduce 5% of the carbon dioxide ton per employee in 5 years, and we aim to further manage the greenhouse gas emissions such as better utilize the office electricity by turning off lights in a more timely manner.

5. ENVIRONMENTAL ASPECT

Online electric prescriptions and digitalization services

In 2022, our internet hospitals issued approximately 170 million online prescriptions which not only helped millions of people acquired medical services but also saved energies and resources from issuing paper prescriptions and patients commuting to hospitals.

Our SaaS systems have been installed in approximately 2,600 hospitals and more than 190,000 pharmacy stores which also help to reduce paper usage from our customers and improve their working efficiency by digitalizing their working processes and documentations.

All these efforts can help saving energies and resource consumption among the value chain of healthcare services.

Medical wastes management

Our hazardous materials mainly include waste electronic items generated from daily office use and near-validity medical products. In 2022, based on our supply chain related data, we have 25.54 ton of hazardous materials which were handed over to qualified professional institutions for scrap. The non-hazardous wastes mainly include waste paper, cardboard boxes and garbage generated from daily office, which are handed over to the property company for unified classification and treatment. However, because we use shared office building and office wastes processing is included in property service, we have no statistical data on non-hazardous wastes quantity.

In term of the disposal of dangerous waste products with special management regulations, we have formulated the "Management System for Near-Expiration and Non-conforming Drugs and the Management System for Drug Returns" in accordance with the "Good Supplying Practice of Medicines (GSP)", formulated different treatment methods according to the nature of the drugs, regularly concentrated on cleaning up and destroying substandard drugs, strictly controlled the treated wastewater, waste residue, outsourced packaging and other waste, and prevented potential risks such as personal injury incidents and environmental pollution incidents caused by drug leakage. Drugs with a near-expiration period shall be returned to their suppliers or handed over to qualified professional institutions for unified processing according to management regulations.

In terms of the target setting, we aim to reduce the hazardous and non-hazardous wastes by 5% in 5 years. We will more rigorously manage the turnover of our products to further reduce the volume of near-validity medical products.



6. SOCIAL ASPECT

6.1 Employment and labor standard

ClouDr adheres to the principles of fairness and justice in the employment of its staff. The Company does not discriminate based on gender, age, ethnicity, nationality, marital or reproductive status, religious beliefs, political stance, or any other factor. Our Human Resources Management Policy also includes corresponding regulations to manage discriminatory behavior. Additionally, the Company provides suitable job positions for disabled individuals. As at December 31, 2022, the Group had a total of 1,349 employees across 96 cities in China, female employees represented 48% of the total workforce. In our senior management team, the female senior management represented 40% of the total senior management team.

ClouDr strictly abides by the Labor Contract Law of the People’s Republic of China, Contract Law of the People’s Republic of China, and other laws and regulations. The Company prohibits the employment of individuals under the age of 18 and sets strict screening procedures during recruitment and hiring. The Company respects and safeguards the legal rights and interests of each employee. The Human Resources Management Policy specifically outlines employee rest and leave arrangements and holiday benefits. In case of any non-compliance in relation to employment of child labor, we will settle all their salaries, terminate the labor contract with them, and take remedial measures such as escorting the child labor to the guardian office. Meanwhile, employees who hire child labor in violation of regulations will be held accountable in accordance with the law. During the Reporting Period, there were no incidents of child labor or forced labor. Moreover, the Company has established “ClouDr Female Care Ambassadors” and a “Female Employee Care Emailbox” to provide more care and assistance to the female employees.

As at December 31, 2022, the Group had a total of 1,349 employees, comprising 453 employees in Hangzhou, 158 employees in Shanghai, and 738 employees in other offices in China. The Group also had over 2,621 flexible staffing as of December 31, 2022 to support business development activities mostly in lower tier cities.

Below is an overview of our full-time employee employment and employee turnover during the Reporting Period:

Indicator		Unit	2022	
Full-time employee employment	Total number of full-time employees	Person	1,349	
	By gender	Female employees	%	48
		Male employees	%	52
	By age	Above 50 years old	%	1
		40–49 years old	%	15
		30–39 years old	%	54
		Below 30 years old	%	30
	By region	South region	%	8
		North region	%	8
		East region	%	70
West region		%	13	
Full-time employee turnover	Total number of full-time employees leaving office	Person	851	
	Full-time employee turnover rate	%	39	
	By gender	Female full-time employees	%	29
		Male full-time employees	%	71
	By age	Above 50 years old	%	0
		40–49 years old	%	7
		30–39 years old	%	48
		Below 30 years old	%	45
	By region	South region	%	14
		North region	%	12
East region		%	54	
West region		%	20	

6. SOCIAL ASPECT



6.2 Health and safety

ClouDr cares about the occupational safety and health of its employees. The Company complies with laws and regulations such as the Occupational Disease Prevention and Control Law of the People's Republic of China, the Work Safety Law of the People's Republic of China, and provides a safe and comfortable working environment for all employees. Our Human Resources Management Policy highlight the importance of the health and safety of our employee, and ensure a series of actions to protect employees' health and safety. For instance, the policy clearly stated to reimburse the regular health condition checkup fees of our employees, and to provide health kits in the workplace to ensure the safety and health of employees, and avoid occupational hazards. There have been no work-related deaths or work-related injuries in the past. During the Reporting Period, there were no cases of work-related fatalities and work-related injuries.

We provide supplementary commercial insurance for employees to offer comprehensive medical protection. The Company arranges regular physical examinations for employees to help them effectively cope with diseases and unexpected risks. The Company also actively encourages employees to have a healthy lifestyle and work-life balance. To promote employees' physical and mental health, the Company regularly organizes team-building activities with diverse forms of entertainment to facilitate communication and interaction among employees.

During the COVID-19 lockdown in 2022, we made efforts to procure multiple resources to ensure the health of employees and their families. The Company provided free essential goods such as vegetables, meat, grains, and oils to colleagues who had difficulties purchasing daily necessities. The Company also set up a hotline for psychological counseling to provide comprehensive care for employees' physical and mental health.

Below is an overview of the health and safety condition of our employees during the Reporting Period:

	Indicator	Unit	2020	2021	2022
Health and safety	Number and rate of work-related employee deaths	%	0	0	0
	Number of workdays lost due to employee work-related injury	Day	0	0	0

6. SOCIAL ASPECT



6.3 Employee recruitment and management provisions

The Group's explicit guidelines for hiring and employment practices are as follows: The Company's human resources demand strategy is implemented by the human resources department, and the recruitment process can be carried out by combining internal and external approaches. When submitting a human resource requirement plan, each department must include the job functions of the desired position, the requirements for the candidate, and the person to whom they report.

We choose high potential talents in accordance with the "ClouDr Value", and we are confident that individuals who fit the "ClouDr Value" are capable of performing well in ClouDr for a variety of positions with high development potential.

6. SOCIAL ASPECT

**ClouDr Value**

Behavior Value (行為目標)	Strong execution Effective collaboration Courageous innovation High say-do ratio Honesty and trustworthy
Task-based Value (業務目標)	Vary by functions and teams

Campus recruiting, social recruitment, internal recruitment, and other recruitment methods are the Group's primary methods of hiring. The Group's hiring policies are as follows: Open recruitment to choose the most qualified candidates; internal employees must have priority under equal circumstances.

6.4 Employee compensation, benefit and activities

The Group will offer employees a compensation and welfare structure that is fair on the inside and competitive externally in the industry to ensure the long-term growth of ClouDr Group Limited. In order to maintain its sustainable competitiveness, the Group will also routinely gather and analyze pertinent compensation data in the target markets. The two types of compensation are cash income and non-cash income. Cash income includes items such as base salaries, bonuses, and so forth. Non-cash income includes items such as social insurance and provident funds, internal company benefits, and so forth. Since the employees joined, the Group has paid their social insurance and provident fund.

Employees receive full compensation for their yearly vacation and full pay for their sick leave when it comes to holiday pay. Employees must be paid for additional sick days based on 80% of the local province's minimum salary for the current year (specific rules that apply only in particular places must be followed). The whole day's pay will be taken out for personal leave. Additionally, the Company will pay the employees' basic salaries throughout their maternity leaves, paternity leaves, maternity check leaves, paternity leaves, paternity leaves, family planning leaves, and public holidays.

6.5 Talent development and training

ClouDr considers talent development and training as a key task for the Company's growth. The Company continually optimizes and perfects its training system to promote the continuous growth of talents. We believe that the Company's efforts to attract and cultivate talent demonstrate its commitment to investing in its workforce, which can ultimately contribute to the company's long-term success and sustainability.


The Company's training system comprehensively covers courses for different groups, such as the "New Employee Induction Training" and "Middle and Senior Managers Induction Workshop" for new employees, the "New Manager Training Camp" for frontline managers, the "Advanced Leadership Program" for middle and senior managers, as well as corresponding external training courses, and the "ClouDr Employee Charging Station" and "ClouDr Learning Day" to enhance the general skills of all staff.



6. SOCIAL ASPECT

In 2022, 1,755 of our full-time employees (including the leaving employees) attended various types of employee development training sessions, details are as below:

Indicator		Unit	2022	
Full-time employee training	Total number of full-time employees trained	Person	1,755	
	Total training hours of full-time employees	Hour	33,725	
	Average training hours of full-time employees	Hour	25	
	By gender	Total training hours of female full-time employees	Hour	16,188
		Total training hours of male full-time employees	Hour	17,537
	By employee type	Total grass-roots full-time employees trained	Hour	489
		Total middle management employees trained	Hour	2,500
		Total senior management employees trained	Hour	528



6. SOCIAL ASPECT



While enhancing employees' skills, the Company also provides a smooth career development channel for employees and motivates them to develop comprehensively through promotions, job rotations, and other methods. In the meanwhile, the Company continues to increase its efforts in technology innovation and talent cultivation, actively attracting chief scientists, and successfully obtained a bronze medal through the evaluation of the post-doctoral workstation, which improves the overall talent development level.



6. SOCIAL ASPECT

6.6 Anti-corruption

We have in place an anti-bribery and anti-corruption policy to safeguard against any corruption within our Company. The policy explains potential bribery and corruption conduct and our anti-bribery and anti-corruption measures. Improper payments prohibited by the policy include bribes, kickbacks, excessive gifts or facilitation payment, or any other payment made or offered to obtain an undue business advantage. In particular, we issued our policy relating to anti-bribery and anti-corruption in January 2021, which provides guidance for staff behavior, and the identification, monitoring and reporting of bribery and corruption events. We keep accurate books and records that reflect the substance of transactions and asset dispositions in reasonable detail. We specifically require that the employees submit all reimbursement requests related to entertainment related fee or gifts presented to third parties on behalf of us in accordance with our expense expenditure policy, and specifically record the reason for the expenditure. These expenses should be recorded in the financial system and marked as promotional gift expenses or entertainment expenses as appropriate. In addition, we require our employees to report and obtain pre-approval of all business courtesy expenses with a value of more than RMB300 per capita or equivalent for our review and supervision. We also require that the payment must not be used for any purpose other than those described in the supporting document. Misleading or incomplete entries in our books and records are not acceptable and subject to disciplinary actions. The payment made in violation of the expense approval process, cash management system or reimbursement system is strictly prohibited. Our finance department regularly monitors the effectiveness and supervises the implementation of the policy, and report to our board of directors the applicability, appropriateness and effectiveness of the policy periodically. Any improvement measures determined by our board of directors should be implemented as soon as possible. In addition, we regularly provide anti-bribery and anti-corruption trainings to all of employees. Our legal and compliance department keeps the training records. Furthermore, we have implemented robust internal control policies with regard to third parties for our business operations, including our customers and suppliers.

We also have a dedicated Anti-Money Laundering Policy. The policy contains the definition and regulatory requirement on the money laundering, and the detailed internal management procedures to identify and protect money laundering, including the payment methods which we do not accept due to the money laundering risk considerations, the red flags of money laundering, the internal training rhythms and internal audit requirements and so on.

During the Reporting Period, there was no material anti-corruption or anti-money laundering concerns raised or identified, and to the best of the knowledge of us, there was not any claims from any third party against us on the anti-corruption or anti-money laundering.

Employee education

We requires all employees to sign an “Integrity Declaration” annually to ensure that their business dealings do not conflict with the interests of the Company and to confirm compliance with relevant laws and regulations.

Employees must also conduct self-monitoring in real-time and regularly receive training from the Company’s compliance department. The content of the training include anti-corruption areas such as improper payment, reimbursement standards, channels to raise compliance concerns, etc. The training records and assessment results are included in KPI evaluations.

To regulate employee hospitality behavior, we has established standards for entertainment, hospitality, and gift-giving based on relevant laws and regulations, business characteristics, and benchmarking against similar companies in the market. These guidance is documented in our Employee Expense Management Policy and Employee handbook and will be updated regularly. Exceeding the standard is generally not allowed, and in special circumstances, approval from the highest level of the Company is required.

6. SOCIAL ASPECT

Corruption report and investigation

We welcome every employee to communicate with the Company in a timely manner when they encounter integrity concerns about themselves or others.

We provide the highest level of confidentiality for all employee feedback to ensure that relevant information is not leaked. Each employee can contact the compliance department through email at compliance@91jkys.com to raise compliance related concerns anonymously, and the management takes any compliance concerns seriously.

For issues raised by employees, the internal audit team and compliance committee will analyze them one by one with high confidentiality and execute relevant inspection procedures if necessary. As of December 31, 2022, there was no compliance cases raised by employees or compliance related litigation.

During the investigation of fraud and improper business activities, the internal control and internal audit personnel of the Company shall promptly report to the organization management under the following circumstances:

- (1) It can be reasonably believed that fraud and improper business activities have occurred and require in-depth investigation;
- (2) Fraud and improper business activities have resulted in significant misrepresentations in financial statements disclosed to the public; and
- (3) Evidence of criminal clues has been found and should be transferred to judicial authorities for processing.

	Indicator	Unit	2022
Anti-corruption	Number of anti-corruption lawsuits	Cases	0
	Signing rate of Employee Integrity Declaration letter	%	100

6.7 Supply chain management

Relying on our leading supply chain capabilities and continue effort on enhancing supply chain management system, we has built a mature and effective supplier access and management mechanism. Through a comprehensive supply chain system, we help the development of the industry and promote the improvement of environmental, social and governance capabilities of our supplier partners.

In cooperation with business suppliers, we established an on boarding process that conducts reviews on the needed licenses and qualifications of all suppliers to ensure they all meet the relevant requirements and revisions of national policies and regulations. Suppliers with excellent product quality, reasonable prices, good reputation and good discipline will be included into our qualified supplier database. We also place a strong emphasis on the supply chain's sustainable development and closely monitor the the environmental and social performance of our suppliers. In addition to the attention on the quality, operations, products and quality assurance, we also understand the environmental, social, and ethical issues related to our suppliers' businesses and have established minimum standards for pertinent issues to determine whether our suppliers have complied with applicable laws and regulations and other required standards in terms of environmental pollution, health and safety, forced labor, and child labor. We perform negative news search and sample based onsite review during the supplier onboarding process to monitor the ESG aspects of our suppliers. Through the above review process and regular inspections of the environmental and social performance of the suppliers, we minimise the potential environmental and social risks in the supply chain.

6. SOCIAL ASPECT

The whole procurement process and all procurement activities are managed in a standardized manner. We have formed Know Your Suppliers processes (“KYS”) and competitive bidding policy and drive procurement process standardization by applying OA system and investing on comprehensive supply chain management systems. We have set up comprehensive supplier inspection and monitoring criteria, focusing on the integrity of supplier qualifications, operational compliance, cost and delivery quality. Our relevant team actively monitors the cooperation status and performance indicators of suppliers and conducts on-site inspections of suppliers’ operating sites if necessary. In addition, we provide training on employee responsibility, supplier screening, and anti-fraud for employees involved in the procurement process. As of December 31, 2022, we onboarded 917 new suppliers, including 297 indirect sourcing suppliers and 620 direct suppliers.

Indicator		Unit	2022	
Supplier management	Total number of new suppliers	Company	917	
	By supplier type	Direct supplier	Company	620
		Indirect supplier	Company	297
	By region	Suppliers from mainland China	Company	899
		Suppliers from Hong Kong, Macau and Taiwan and overseas suppliers	Company	18
		Percentage of suppliers who went through the KYS onboarding processes	%	100

6.8 Product responsibility

We care about the quality and safety of medical and healthcare products and services to our customers and patients, and we aim to bring digital healthcare to every household. We strictly abide by the relevant laws and regulations and actively keep aligning our internal policies with the requirements of the state and society. By implementing and operating a well-established quality and safety management system, conducting a solid inspection of management processes, products and services in a routine manner, we highly care about the health of our customers and patients, and ensure the products and services that we provide to the greatest extent.

We have a customer service team to handle products and services relating to the customer’s complaints. We also built standard processes for the customer complaints by different types of complaints and owners.

6. SOCIAL ASPECT



We are also committed to protecting data privacy and security. We have established and maintain a strict platform-wide policy on data collection, processing and usage. We sometimes collect data from our online platform users, which are strictly limited to personal information and other data that are necessary for us to provide services to our users. We obtain prior consent from users for all user data we collect, and have adopted stringent policies to ensure that our collection and usage of data is in compliance with the relevant laws and regulations. We do not monetize any of the data we collect. The registration processes require the user to provide consents to allow us to collect, process and use data necessary for providing our services. To ensure the confidentiality and integrity of our data, we maintain a comprehensive and rigorous data security program. We conduct back up of our operating data on a regular basis offline and in separate and various secured data back-up systems to minimize the risk of data loss. We back up our data on a daily basis in various distributed secured data storage systems to minimize the risk of data loss. We also conduct frequent reviews of our back-up systems to ensure that they function properly and are well maintained. Our detailed protocol for operation and maintenance management, monitor and alert mechanisms, network security management and disaster recovery ensures our operating continuity. We have also established a business continuity plan in case of catastrophic events, such as natural or unnatural disasters that could lead to various business interruptions, such as power failures, network failures, or server power outages. In addition, our maintenance team closely and constantly monitors for common technical issues and the usage of resources such as central processing units and memory and alerts our technical team of unusual technical difficulties. In addition, we have set up an emergency response team to annually conduct disaster recovery drills on important systems and continuously improve our systems. Our back-end security system is capable of handling malicious attacks to safeguard the security of our platform and to protect the privacy of our users.

During the Reporting Period, there were no products recalled by the Group due to safety and health reasons. In addition, no complaints were received about the products and services delivered that could have a material impact on the Group's operations. Furthermore, there had been no material cybersecurity and data protection incidents with respect to data or personal information theft, leakage, damage or loss, or any claim from any third party against us on the ground of infringement of such party's right to data protection as provided by any applicable laws and regulations in mainland China, or other legal proceedings, administrative or governmental proceedings, pending or, to the best of the knowledge of us, threatened against or relating to us.

Intellectual Property Management

We have designed and adopted strict internal procedures to ensure the protection of our intellectual property rights.

In accordance with these procedures, our in-house legal department performs the basic function of reviewing and updating the form of contracts we enter into with our customers and suppliers. Our legal department as well as business operation teams examine the contract terms and review all relevant documents for our business operations, including licenses and permits obtained by the counterparties or us to perform contractual obligations and all the necessary underlying due diligence materials, before we enter into any contract or business arrangements.



6. SOCIAL ASPECT

We also have in place detailed internal procedures to ensure that our in-house legal department reviews our products and services, including upgrades to existing products, for regulatory compliance before they are made available to the general public. Our in-house legal department is responsible for obtaining any requisite governmental pre-approvals or consent, including preparing and submitting all necessary documents for filing with relevant government authorities within the prescribed regulatory timelines and ensuring all necessary application, renewals or filings for trademark, copyright and patent registration have been timely made to the competent authorities

Product and Service Compliance Management

1. *Online Hospitals and Medical Services*

We operate several online hospitals and we provide strong medical services to our customers and patients to improve the efficiency of healthcare services. We implemented internal management policies and procedures to strictly follow a series of relevant laws of regulations including below:

“Measures for the Administration of Internet Diagnosis and CI Treatment (for Trial Implementation),” “Measures for the Administration of Online Hospitals (for Trial Implementation),” “Rules for the Regulation of Internet Diagnosis and Treatment (Draft),” “Specifications for the Administration of Remote Medical Services (for Trial Implementation),” “Law on Licensed Medical Practitioners of the PRC,” “Notice on Further Promoting the Development and Standard Administration of Online Healthcare Services by the National Health Commission Office,” “State Council’s Opinions on Promoting the Development of ‘Internet Plus Health Care’” and other relevant regulations.

2. *Internet Information and Technology*

We fully understand and support the compliance of internet information and technology. We invested and worked with relevant experts from the industry and government to ensure the information on our platform are secured and well protected. We also provided a series of trainings to employees to promote the culture and ensure the solid execution. We implemented internal management policies and procedures to strictly follow a series of relevant laws of regulations including below:

“Cybersecurity Law of the PRC,” “Data Security Law of the PRC,” “Personal Information Protection Law of the PRC,” “Administrative Measures for National Health Medical Big Data Standard, Safety, and Service (for Trial Implementation),” “Information Security Technology — Personal Information Security Specification (2020 Version),” and other relevant regulations.

3. *Medication and Health Product Management*

We provide medication and health products to our pharmacy customers and online customers. We pay great attention to the safety of those products to ensure the healthcare condition of our customers and patients. We implemented internal management policies and procedures to strictly follow a series of relevant laws of regulations including below:

6. SOCIAL ASPECT

“Food Safety Law of the PRC,” “Drug Administration Law of the PRC,” “Product Quality Law of the PRC,” “Good Supply Practice for Pharmaceutical Products,” “Measures for the Administration of Pharmaceutical Operation License,” “Administrative Measures for the Supervision and Administration of Circulation of Pharmaceuticals,” “Measures Regarding the Administration of Drug Information Service Over the Internet,” “Regulations on the Administration of Drugs Containing Stimulants,” “Administrative Measures for Toxic Drugs for Medicinal Use,” “Notice on the Implementation of Categorized Administration of Prescription Drugs and Non-Prescription Drugs,” “Notice of the State Food and Drug Administration (SFDA) on Further Strengthening the Administration of Purchase and Sales of Oral Compound Preparations Containing Narcotic Drugs and Tramadol,” “Notice of the SFDA and the National Health and Family Planning Commission (NHFPC) on Strengthening the Administration of Compound Codeine Oral Liquid Preparation,” “Notice on Strengthening the Supervision and Administration of Certain Compound Preparations Containing Special Drugs,” “Notice of the SFDA, the Ministry of Public Security, and the NHFPC Announcing the Catalogs of Narcotic Drugs and Psychotropic Drugs,” “Notice of the SFDA, the State Administration of Traditional Chinese Medicine, the National Health Commission, the National Healthcare Security Administration on Ending the Trials of Traditional Chinese Medicinal Granula,” “Regulation on the Control of Narcotic Drugs and Psychotropic Drugs,” “Notice of the SFDA on the Cancellation of Registration Certificates for Medicinal Products,” “Regulation on the Supervision and Administration of Medical Devices,” “Regulation on the Administration of Precursor Chemicals,” “Narcotics Control Law of the PRC,” “Measures for the Administration of Radioactive Pharmaceuticals,” and other relevant regulations.

4. Internal Control System

In terms of compliance, we formulated a total of 125 management regulations and operating procedures, including the Qualified Supplier Management System, the Good Supply Practice Management System, the Internet Hospital Management System, and the Data Management System.

Product and Service Responsibility Management

Through our well-established internal control system and product safety policies, we maintain and monitor the safety and quality of our products and medical services. We rigorously control the risks during the delivery of our healthcare and medical services in order to improve the quality, customer satisfaction and medical service effectiveness. Consequently, we improve the service quality by ensuring the appropriate online medical consultation and prescription services.

1. Healthcare Service Quality and Safety

The expertise and service quality delivered by our internet hospitals is vital to optimizing patients’ experience. Therefore, we continuously monitor the risks associated with the healthcare service, and strictly comply with the risk control policy to achieve efficient risk governance, and eventually guarantee the patients’ experience and safety.

(a) Doctor onboarding control and governance mechanism

We follow a strict qualification evaluation process, quality inspection procedure, and medical service quality control and assurance mechanism.



6. SOCIAL ASPECT

First, doctors have to hold a registered qualification certificate (except for those still in the training period) before they register on our platform. Those doctors with prescriptive authority also need to provide such certificate. Through real-name authentication, face recognition, verification on qualification certificates and professional titles, we ensure that all the registered doctors meet the qualification requirements. We also follow the requirements of National Health Commission of the People's Republic of China, we register our doctors and put on records with National Health Commission for the multi-sited doctors.

Second, to ensure the effectiveness of the medical services, every prescription processed by our platform will be evaluated by professional pharmacists.

Third, we construct a strict risk control and medical service quality evaluation system. We provide standard trainings to our doctors and conduct regular reviews and evaluations of the professional service provided by them.

(b) *Internet Hospital Management*

We operate several Internet Hospitals, and we strictly follow regulations to ensure the compliance and safety. We have a dedicated team for the internet hospital management including license compliance management, daily operating management and data security management. We periodically review the "Internet Hospital Management" policies and management procedures, and highly responsive to the newly launched regulations and users' feedback. We keep strengthening the compliance monitoring and management.

(c) *Quality control of online medical services*

We provided nearly 170 million online prescriptions in 2022. We highly care about the safety and effectiveness of our online medical services. For every online prescription, we ensure the safety by implementing robust control systems including the doctor management procedures, AI-powered double quality control which is supported by the ClouDr Core Medical Engine, and daily review mechanism.

2. **Healthcare Products Quality and Safety**

In 2022, we ensured our products such as medical devices, consumables and drugs are safe and qualified by deploying various quality management policies and procedures. We have a dedicated supply chain team to manage the suppliers onboarding, the product quality and safety, the inventory management, and scrap control management.

(a) *Suppliers onboarding control and governance mechanism*

We only partner with the suppliers with robust compliance manner and high quality standard. We have a robust Know Your Supplier process to understand the potential suppliers and evaluate the risks. On a regular basis, we refresh the background check of our suppliers to ensure the compliance.

6. SOCIAL ASPECT

(b) *Product quality and safety control*

We implement robust quality and safety control procedures in our supply chain. The Quality Control team performs inspections on every batch of products before accepting to our warehouse. The Quality Control team also performs regular check on the products approaching expiration date to ensure every products sold to our customers and patients are with high quality and safety condition.

(c) *Scrap control management*

For the products which are expired or unqualified, our Quality Control team initiates scrap process. We only partner with professional medication scrap companies to scrap the medication to ensure the compliance and safety of environment and society.

6.9 Responsibilities to customers

As the largest digital chronic condition management solution service provider in China, we serve a large number of To-B customers and To-C individual users/patients, including approximately 2,600 hospitals which installed our hospital chronic condition management SaaS system, more than 193,000 pharmacies which installed our pharmacy SaaS system, more than 98,000 registered doctors and approximately 28.5 million registered users.

Hospitals




With substantial rising demand for healthcare, China's healthcare industry is undergoing unprecedented supply-side reforms, and the digital systems can support to uplift the healthcare industry efficiency.

ClouDr. Yihui, our hospital SaaS is designed to digitalize chronic condition management to improve hospitals' operational efficiency and treatment effectiveness. It facilitates hospitals in creating and maintaining EMR for their chronic condition patients. It can connect to in-hospital medical AIoT equipment. Because *ClouDr. Yihui* acts as a "plug-in" or extension of existing Hospital Information System ("HIS") and laboratory information systems ("LIS"), it can work seamlessly with hospitals' current systems without the need of major revisions to hospitals' systems. With that, our hospital SaaS can replace the manual work previously required by the doctors and nurses, and reduce the manual error risks and associated diagnosis risks.

Real-time Information Integration



6. SOCIAL ASPECT



6. SOCIAL ASPECT



Retail Pharmacies

As part of the China healthcare industry unprecedented supply-side reforms, a series of regulations promotes the growth of out-of-hospital healthcare capabilities, and one of those are outflow of prescribed drugs from hospitals to pharmacies. Retail pharmacies now are allowed to sell prescribed drugs with qualified prescriptions. We provide online consultation and prescription services to retail pharmacies through our Pharmacy SaaS. In 2022, our online internet hospitals generated nearly 170 million online prescriptions, and the majority of them are generated in the partnered retail pharmacies. More than 99% of the walk-in patients can get remote medical services in the pharmacies within 180 seconds. The SaaS product and internet hospitals support the healthcare industry supply-side reforms and empower retail pharmacies to enhance medical service capabilities.

Communities

With the national target of “Healthy Community 2030”, as of December 31, 2022, we partnered with communities in Beijing and Shanghai to build the “ClouDr. Healthcare Stations” which offer free online consultation services to residents in the communities through our platform. We have also set up AI-empowered robots in these stations to allow residents to connect their own medical devices for better consultation results.



6. SOCIAL ASPECT

6.10 Community investment and participation

Social welfare initiatives, in our opinion, are not only the Company's required social responsibility but also essential to its long-term development. We insisted on the continuous development of public welfare undertakings and strives to fulfill social responsibilities. In 2022, the Group has spent more than 2.5 million RMB on the public donation, the free public medical services, and the support to the postdoctoral research workstation and so on.

Online free medical services and medical product donation to communities

Since the outbreak of the Covid-19 epidemic, relying on our strong supply chain and industry leading digital chronic disease management service capabilities, we have continued to launch online free medical services for the Covid-19 epidemic and chronic disease management, and have joined hands with public hospitals and pharmacies across the country to extend high-quality medical and health services to the "last mile", so that patients can solve the needs of seeking medical treatment and medicine anytime anywhere during the epidemic period. We also cooperate with medical experts and pharmacies from more authoritative medical institutions to improve the efficiency of digital health management services through various forms and better protect public health.

During the outbreak of COVID-19 in Guangdong, Jiangsu, Yinchuan, and other areas, in order to reduce the risk of transmission caused by medical contact and solve the problem of difficulty in registration and treatment for chronic disease patients during the epidemic, we cooperated with the China Pharmaceutical Education Association, Yinchuan Internet + Medical Health Association, etc., based on our digital chronic disease management platform, assembled a team of high-quality doctors and experts from public hospitals, opened an online anti-epidemic area to provide one-to-one free consultation, drug delivery, health consultation, and other services for chronic disease patients. We worked together with doctors to fight against the epidemic and contributed special public welfare efforts to support frontline anti-epidemic and relieve the heavy pressure on the medical system.

During 2022 Chinese New Year, we customized epidemic prevention packages including protection equipment and donated to Hangzhou local communities. This donation aimed to bring warmth to local residents and support them in fighting against the epidemic.



6. SOCIAL ASPECT

Zhejiang Province postdoctoral research workstation

In June 2022, ClouDr established a postdoctoral research workstation, which will continuously attract more outstanding postdoctoral talents and cultivate young scientific research talents through the platform's talent development function. This move will further unleash the internal organizational and talent development potential, support the company's long-term stable development with strong organizational construction capabilities, and enhance ClouDr's core competitiveness. The establishment of the postdoctoral workstation marks a new stage in the development of the company's science and technology enterprise development strategy. It will promote the talent cultivation level of both the enterprise and the partner university and promote the development of scientific research.

Additionally, it will help to gradually establish an industrial ecosystem with science and technology enterprises in Yuhang District, Zhejiang Province, injecting strong power into the creation of a leading area for the digital economy in Yuhang District.



7. GOVERNANCE ASPECT

The corporate governance report of ClouDr Group Limited has been disclosed in the annual report published in the websites of the Hong Kong Stock Exchange and the Company on 28 April 2022 respectively. The following is the summary of the core contents of corporate governance management.

7.1 BOARD OF DIRECTORS AND BOARD COMMITTEES

The Board is responsible for the overall leadership of the Group, oversees the Group's businesses, strategic decisions, monitors performance and takes decisions objectively in the best interests of the Company.

The Board has delegated the authorities and responsibilities for day-to-day management and operation of the Group to the senior management of the Group. To oversee particular aspects of the Company's affairs, the Board has established three Board committees including the audit committee, the remuneration committee and the nomination committee. The Board has delegated to the Board committees responsibilities as set out in their respective terms of reference. All Board committees are provided with sufficient resources to perform their duties.

All Directors shall ensure that they carry out their duties in good faith, in compliance with applicable laws and regulations, and in the interests of the Company and its Shareholders at all times.

The Board regularly reviews the contribution required from a Director to perform his responsibilities to the Company, and whether the Director is devoting sufficient time performing such responsibilities.

Board Composition

As at April 28, 2023, the Board currently comprises five Directors, consisting of one executive Director, one non-executive Director and three independent non-executive Directors. The members of the Board of the Company during the Reporting Period are listed as follows:

Executive Director

Mr. Kuang Ming (匡明) ("**Mr. Kuang**") (*Chairperson and Chief Executive Officer*)

Non-executive Director

Mr. Lee Kar Chung Felix (李家聰)

Independent Non-executive Directors

Dr. Hong Weili (洪偉力)

Mr. Zhang Saiyin (張賽音)

Mr. Ang Khai Meng

7. GOVERNANCE ASPECT

Executive Director

Mr. Kuang Ming (匡明), aged 42, is the founder, executive Director, chairman of the Board, chief executive officer, chairperson of the Nomination Committee and a member of the Remuneration Committee of the Company. Mr. Kuang is primarily responsible for the overall strategic planning, business direction and research and development initiatives of our Group. Mr. Kuang is currently the legal representative and an executive director and/or general manager of certain subsidiaries of our Group, including Hangzhou Kangsheng Health Management Consultant Co. Ltd* (杭州康晟健康管理諮詢有限公司), Hangzhou Kangming, 91health Shanghai Limited* (上海運臻網絡科技有限公司), Shanghai Kangmeng Health Management Consultation Co., Ltd, Hainan Zhiyun Distance Medical Center Co., Ltd, Hainan Youyi Technology Co., Ltd, Yinbang Insurance Brokerage, Shenzhen Yinsiubao Technology Co., Limited, 91health Hangzhou Limited* (杭州智雲匯醫科技有限公司), Jiangsu Xinwange Medical Technology Co., Ltd, Hainan Zhiyun Internet Hospital Co., Ltd and Guangxi Zhiyun Health Technology Co., Ltd..

Mr. Kuang has over 15 years of experience in healthcare and technology industries in the PRC and the United States. Prior to founding of our Company, Mr. Kuang was a senior strategic marketing manager in APAC at Johnson & Johnson (NYSE: JNJ) between July 2012 and January 2015. From October 2011 to April 2012, Mr. Kuang worked in the US division of Johnson & Johnson. From April 2006 to September 2010, Mr. Kuang served in various technical roles for APAC Business Development at Intel China.

Mr. Kuang received a bachelor's degree in Electrical Engineering from Tongji University in July 2002, and a master's degree in Communication Engineering from Shanghai Jiaotong University in March 2006. He also received a master's degree in Business Administration from Cambridge Judge Business School in March 2012.

Non-executive Director

Mr. Lee Kar Chung Felix (李家聰), aged 41, is a non-executive Director and a member of the Audit Committee. He is primarily responsible for supervising and providing guidance and independent judgement to the Board.

Mr. Lee is currently a senior vice president of Chow Tai Fook Enterprises Limited with responsibilities in making investments in the healthcare sector in Asia and globally since September 2014.

Mr. Lee is also an executive director of UMP Healthcare Holdings Limited (a company listed on the Stock Exchange, stock code: 722) since August 2015 and an independent non-executive director of China Resources Medical Holdings Company Limited (a company listed on the Stock Exchange, stock code: 1515) since August 2015 and an independent non-executive director of Asymchem Laboratories (Tianjin) Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 002821, and the Stock Exchange, stock code: 6821) since June 2021.

He has over 15 years of experience in law and finance. He served as a solicitor with the law firm Freshfields Bruckhaus Deringer from January 2005 to February 2008, an analyst in the investment banking department of UBS AG, Hong Kong branch from March 2008 to January 2009. He then joined Deutsche Bank AG, Hong Kong branch and last held the position of director in the Corporate Finance Division, where he worked from January 2009 to August 2014.

Mr. Lee obtained a bachelor's degree of Laws from the London School of Economics and Political Sciences and a postgraduate certificate in Laws from the University of Hong Kong in July 2003 and June 2004, respectively. He is a solicitor of the High Court of Hong Kong since September 2007 and a solicitor (non-practising) in the Senior Courts of England and Wales since February 2013.

7. GOVERNANCE ASPECT

Independent non-executive Directors

Dr. Hong Weili (洪偉力), aged 53, is an independent non-executive Director, the chairperson of the Remuneration Committee, a member of the Audit Committee and a member of the Nomination Committee. He is primarily responsible for supervising and providing independent judgement to the Board.

Dr. Hong has extensive experience in finance and investment in both Chinese and overseas financial institutions and capital markets. He was the president and chief research officer of CMC Holdings from November 2016 to September 2018. Prior to joining CMC Holdings, he was a partner of the Gopher Asset Management from February 2014 to March 2016, in charge of private equity and venture capital funds of funds and direct investments. Dr. Hong also served as the managing partner of KTB Ventures from April 2008 to April 2012, and the head of business development in ING China from June 2004 to July 2007.

Dr. Hong also serves as an independent director for Dingdong (Cayman) Limited (a company listed on the New York Stock Exchange, stock symbol: DDL), Chindata Group Holdings Limited (a company listed on the Nasdaq Stock Market, stock symbol: CD), and Luolai Lifestyle Technology Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 002293).

Dr. Hong currently serves as a guest professor and a supervisor of the master degree program in the School of Economics of Fudan University; and a guest professor of the Fanhai International School of Finance. He is also the vice chairman of the Global Alumni Association of the Fudan University.

Dr. Hong received both of his bachelor's and doctor's degrees in Economics from Fudan University.

Mr. Zhang Saiyin (張賽音), aged 43, is an independent non-executive Director, the chairperson of the Audit Committee, a member of the Remuneration Committee and a member of the Nomination Committee. He is primarily responsible for supervising and providing independent judgement to the Board.

Mr. Zhang served as a director for MINISO Group Holding Limited ("**MINISO**") (a company listed on the New York Stock Exchange, stock symbol: MNSO, and the Stock Exchange, stock code: 9896) from December 2018 to January 2023, and chief financial officer and executive vice president from October 2018 to January 2023. Prior to joining MINISO, Mr. Zhang served as the chief financial officer between June 2015 and July 2017 and multiple finance leadership roles between April 2011 and May 2015 at China Resources Textiles (Holdings) Company Limited and China Resources Fashion (Holdings) Company Limited, both of which are indirectly wholly owned subsidiaries of China Resources (Holdings) Company Limited. From September 2009 to March 2011, Mr. Zhang worked as a manager in the finance department of Shenzhen Jinjia Color Printing Group Co., Ltd. (a company listed on the Shenzhen Stock Exchange, stock code: 002191, now renamed as "**Shenzhen Jinjia Group Co., Ltd.**"). Between July 2005 and September 2009, Mr. Zhang served as a senior auditor at Deloitte, Shenzhen branch. He worked at the international financing department of ZTE Corporation (a company listed on the Shenzhen Stock Exchange, stock code: 000063, and the Stock Exchange, stock code: 763) between March 2004 and July 2005.

Mr. Zhang received his bachelor's degree in Accounting from Huazhong Agricultural University in China and his master's degree in Accounting and Finance from University of Birmingham in the United Kingdom. Mr. Zhang is also a fellow of Association of Chartered Certified Accountants.

7. GOVERNANCE ASPECT

Mr. Ang Khai Meng, aged 62, is an independent non-executive Director of the Company, primarily responsible for supervising and providing independent judgement to the Board.

Mr. Ang has extensive experience in innovative pharma, generics, biologics, devices, diagnostics, consumables, and consumer health in his 37 years of experience in healthcare industry. He is currently serving as advisor to several companies in China.

In September 2016, Mr. Ang started to serve as the head of China at Roche Diabetes Care. Prior to this, Mr. Ang joined as a vice president of Hospira Asia in July 2011. Mr. Ang also worked as a general manager at Vascular Business Unit of Medtronic in January 2007.

Mr. Ang received his bachelor's degree in Science from Australian National University in Australia, in 1983. Mr. Ang received his Master's degree in Business Administration from Ohio State University in the United States, in 1985.

Board Committees

The Board has established three Board committees, namely the Audit Committee, the Remuneration Committee and the Nomination Committee for overseeing specific aspects of the Company's affairs. All Board committees of the Company are established with defined written terms of reference which deal clearly with their authorities and duties. The terms of reference of each of these committees will be revised from time to time to ensure that they continue to meet the needs of the Company and to ensure compliance with the Corporate Governance Code ("**CG Code**") set out in Appendix 14 to the Listing Rules where applicable. The terms of reference of the Board committees are posted on the Company's website and the Stock Exchange's website and are available to Shareholders upon request.

Audit Committee

The Company established the Audit Committee in compliance with Rules 3.21 and 3.22 of the Listing Rules with written terms of reference in compliance with the CG Code and the roles and responsibilities delegated to the Audit Committee by the Board.

The Audit Committee comprises three members, namely Mr. Zhang Saiyin, Dr. Hong Weili and Mr. Lee Kar Chung Felix. Mr. Lee Kar Chung Felix is a non-executive Director and each of Mr. Zhang Saiyin and Dr. Hong Weili is an independent non-executive Director. Mr. Zhang Saiyin (being our independent non-executive Director with the appropriate professional qualifications or accounting or related financial management expertise) is the chairperson of the Audit Committee.

The terms of reference of the Audit Committee are of no less exacting terms than those set out in the CG Code. The primary duties of the Audit Committee are to review and supervise the financial reporting process and internal controls system of our Group, review and approve connected transactions and provide advice and comments to the Board.

The Audit Committee has reviewed the audited consolidated financial statements of the Group for the year ended December 31, 2022 and has discussed with the independent auditor, KPMG. The Audit Committee confirms that the applicable accounting principles, standards and requirements have been complied with, and that adequate disclosures have been made. The Audit Committee has also reviewed and discussed matters with respect to the accounting policies and practices adopted by the Company and internal control and financial reporting matters with senior management members of the Company.

7. GOVERNANCE ASPECT

During the Reporting Period, the Audit Committee held two meetings, during which matters such as the review of interim financial results and report for the six month ended June 30, 2022, the audit plan for the Reporting Period, effectiveness of the risk management, internal control systems and internal audit function, the implementation status of the internal control's rectification measures and appointment of external auditors and relevant scope of works were discussed.

The Audit Committee also met the external auditor once without the presence of the executive Director during the Reporting Period.

Remuneration Committee

The Remuneration Committee comprises three members, namely Dr. Hong Weili, Mr. Kuang and Mr. Zhang Saiyin. Mr. Kuang is an executive Director and each of Mr. Zhang Saiyin and Dr. Hong Weili is an independent non-executive Director. Dr. Hong Weili is the chairperson of the Remuneration Committee.

The terms of reference of the Remuneration Committee are of no less exacting terms than those set out in the CG Code. The primary duties of the Remuneration Committee are to review and make recommendations to the Board on the terms of remuneration packages, bonuses and other compensation payable to our Directors and other senior management.

During the Reporting Period, the Remuneration Committee held one meeting, during which matters such as the review of the remuneration policy and the remuneration packages of the Directors and senior management of the Company, the review and recommendation of the grant of share awards and the restricted share units to our executive Director and employees of the Company were discussed.

Nomination Committee

The Nomination Committee comprises three members, namely Mr. Kuang, Dr. Hong Weili and Mr. Zhang Saiyin. Mr. Kuang is an executive Director and each of Mr. Zhang Saiyin and Dr. Hong Weili is an independent non-executive Director. Mr. Kuang is the chairperson of the Nomination Committee.

The terms of reference of the Nomination Committee are of no less exacting terms than those set out in the CG Code. The primary duties of the Nomination Committee include making recommendations to our Board on the appointment of Directors and management of Board succession, reviewing the Board Diversity Policy, the Nomination Policy, and assessing the independence of the independent Non-executive Directors. The Nomination Committee considered an appropriate balance of diversity perspectives of the Board is maintained.

During the Reporting Period, the Nomination Committee held one meeting to review the structure, size and composition of the Board and the independence of the independent non-executive Directors and consider the qualifications of the retiring directors standing for election at the forthcoming annual general meeting. The following is a summary of work performed by the Nomination Committee during the Reporting Period:

In assessing the Board composition, the Nomination Committee would take into account various aspects as well as factors concerning Board diversity as set out in the Company's Board diversity policy, details of which will be set out in the section headed "Board Diversity Policy" of the annual report for the year 2022.

7. GOVERNANCE ASPECT

In identifying and selecting suitable candidates for directorships, the Nomination Committee would consider the candidate's character, qualifications, experience, independence (for appointment of independent non-executive Directors), and Board diversity aspects, where appropriate, before making recommendation to the Board. The details of which will be set out in the section headed "Director Nomination Policy" of the annual report for the year 2022.

Board Meetings and Directors' Attendance Records

Pursuant to the code provision C.5.1 of the CG Code, Board meetings should be held at least four times a year at approximately quarterly intervals with active participation of the majority of the Directors, either in person or through electronic means of communication. As the Company was only listed on the Stock Exchange on July 6, 2022 ("**Listing Date**"), only two Board meetings were held during the period from the Listing Date to December 31, 2022. The Company expects to continue to convene at least four regular meetings in each financial year at approximately quarterly intervals in accordance with the code provision C.5.1 of the CG Code. No general meeting was convened during the period from the Listing Date to December 31, 2022.

The attendance records of each Director at the Board and Board committee meetings of the Company held during the period from the Listing Date to December 31, 2022 are set out below:

Name of Directors	Attendance/No. of Meeting(s)			
	Board	Audit Committee	Remuneration Committee	Nomination Committee
Mr. Kuang	2/2	—	1/1	1/1
Mr. Lee Kar Chung Felix	2/2	2/2	—	—
Dr. Hong Weili	2/2	2/2	1/1	1/1
Mr. Zhang Saiyin	2/2	2/2	1/1	1/1
Mr. Ang Khai Meng	2/2	—	—	—

From the Listing Date to December 31, 2022, the chairman of the Board did not hold any meeting with the independent non-executive Directors without the presence of other Directors. The Company will fully comply with the code provision C.2.7 that the chairman of the Board would at least annually hold meetings with the independent non-executive Directors without the presence of other Directors.

7.2 BOARD POLICIES

Board Diversity Policy

The Company adopted a Board Diversity Policy which sets out the approach to achieve diversity of the Board. The Company recognizes and embraces the benefits of having a diverse Board and sees increasing diversity at the Board level, including gender diversity, as an essential element in maintaining the Company's competitive advantage and enhancing its ability to attract, retain and motivate employees from the widest possible pool of available talent. Pursuant to the Board Diversity Policy, in reviewing and assessing suitable candidates to serve as a Director of the Company, the Nomination Committee will consider a number of aspects, including but not limited to gender, age, cultural and educational background, professional qualifications, skills, knowledge, and industry experience. Pursuant to the Board Diversity Policy, the Nomination Committee will discuss periodically and when necessary, agree on the measurable objectives for achieving diversity, including gender diversity, on the Board and recommend them to the Board for formal adoption.

7. GOVERNANCE ASPECT

Our Board has a balanced mix of knowledge, skills and experiences, including management, strategic planning, law, finance, investment, innovative pharma, generics, healthcare and technology industries. The Directors obtained degrees in various areas such as electrical engineering, law, economics, accounting and science. The Nomination Committee is responsible for ensuring the diversity of our Board members. During the Reporting Period, the Board conducted a review of the implementation and effectiveness of the Board Diversity Policy, and believed that the experience and competence of the Directors in all aspects and areas could enable the Company to maintain operation at a high standard.

Going forward, in order to enhance gender diversity of the Board and to achieve the measurable objectives, the Company will appoint at least one female director to join the Board by July 2023. The Nomination Committee will identify and recommend multiple suitable female candidates, including female representatives of our investors, to our Board for its consideration on appointment of a Director.

We will implement policies to ensure gender diversity when recruiting staff to develop a pipeline of female senior management and potential successors to the Board. We will strive to enhance our female representation and achieve appropriate balance of gender diversity with reference to the stakeholders' expectation and international and local recommended best practices. Furthermore, we will implement comprehensive programs aimed at identifying and training our female staff who display leadership and potential, with the goal of promoting them to the senior management or the Board.

The Board will consider setting measurable objectives to implement the Board Diversity Policy and review such objectives from time to time to ensure their appropriateness and ascertain the progress made towards achieving those objectives.

The Nomination Committee will review the Board Diversity Policy, from time to time and as appropriate, to ensure its effectiveness.

Directors' Nomination Policy

The Board has delegated its responsibilities and authority for selection and appointment of Directors to the Nomination Committee of the Company.

The Company has adopted a Director Nomination Policy which sets out the selection criteria and nomination process and the Board succession planning considerations in relation to nomination and appointment of Directors of the Company and aims to ensure that the Board has a balance of skills, experience and diversity of perspectives appropriate to the Company and the continuity of the Board and appropriate leadership at Board level.

The Nomination Committee would nominate the suitable candidates for directorship. In identifying and assessing the suitability and the potential contribution to the Board of a proposed candidate, the Nomination Committee may make reference to certain selection criteria, such as reputation for integrity, professional qualifications and skills, accomplishment and experience in the industry, commitment and relevant contribution, diversity in all aspects. The Nomination Committee shall report its findings and make recommendation to the Board on the appointment of appropriate candidate for directorship for decision and succession planning. The ultimate responsibility for selection and appointment of Directors rests with the entire Board.

From the Listing Date to December 31, 2022, there was no change in the composition of the Board.

7. GOVERNANCE ASPECT

The Nomination Committee will review the Director Nomination Policy, as appropriate, to ensure its effectiveness and the Board possesses the necessary skills, experience and knowledge in alignment with the Company's strategy.

Directors' Remuneration Policy

The Remuneration Committee is responsible for making recommendations to the Board on the Company's policy and structure on the remuneration of all Directors and senior management of the Company and on the establishment of a formal and transparent procedure for developing remuneration policy for the Company for approval by the Board.

It shall also make recommendations to the Board on the remuneration packages of individual executive Director and senior management. The remuneration of individual executive Director and senior management is determined with reference to factors such as the level of remuneration paid by comparable companies, the time commitment and responsibilities of directors and senior management, and the employment conditions of the Company and its subsidiaries.

Dividend Policy

In accordance with code provision F.1.1 of the CG Code, the Company has adopted a dividend policy. According to the dividend policy, payment of dividends depends on a number of factors, including but not limited to: future operations of the Company, general financial condition of the Company, capital requirements of the Company; and any other factors which the Board may consider relevant. Interim dividends may be proposed and/or declared by the Board during a financial year, and any final dividend for a financial year will be subject to the shareholders' approval.

Shareholders' communication policy

The Company considers effective communication with Shareholders is essential for enhancing investor relations and investor understanding of the Group's business performance and strategies. The Company also recognizes the importance of transparency and timely disclosure of corporate information, which will enable Shareholders and investors to make the best investment decisions.

The Company endeavors to maintain an on-going dialogue with Shareholders and in particular, through annual general meetings and other general meetings. The general meetings of the Company provide a platform for communication between the Board and the Shareholders. The chairman of the Board as well as chairperson of each of the Audit Committee, the Remuneration Committee and the Nomination Committee or, in their absence, other members of the respective committees, are available to answer Shareholders' questions at general meetings. The external auditor of the Company is also invited to attend the annual general meetings of the Company to answer questions about the conduct of audit, the preparation and contents of the auditor's report, the accounting policies and auditor independence.

To promote effective communication and to build a communication channel between the Company and the Shareholders, the Company adopts a Shareholders' Communication Policy and maintains a website (www.cloudr.cn), where information and updates on the Company's financial information, corporate governance practices, biographical information of the Board and other information are available for public access.



7. GOVERNANCE ASPECT

During the Reporting Period, the Board reviewed the Shareholders' Communication Policy and ensured its implementation and effectiveness.

7.3 CORPORATE GOVERNANCE FUNCTIONS

Auditor

The Consolidated Financial Statements of the Group for the year ended 31 December 2021 have been audited by KPMG.

KPMG shall retire and being eligible, offer itself for re-appointment, and a resolution to this effect shall be proposed at the AGM.

Joint Company Secretaries

Ms. Liu Mengya ("**Ms. Liu**"), our senior finance director, was appointed as our joint company secretary with effect from the Listing Date. In order to uphold good corporate governance and ensure compliance with the Listing Rules and applicable Hong Kong laws, the Company has also appointed Ms. Fung Wai Sum ("**Ms. Fung**") of Tricor Services Limited (a company secretarial services provider), to act as another joint company secretary and to provide assistance to Ms. Liu for performing her duties as a company secretary of the Company. Ms. Fung's primary contact person at the Company is Ms. Liu.

During the Reporting Period, each of Ms. Liu and Ms. Fung has undertaken not less than 15 hours of relevant professional training in compliance with Rule 3.29 of the Listing Rules.

7.4 SHAREHOLDERS' RIGHTS

To safeguard Shareholders' interests and rights, a separate resolution is proposed for each substantially separate issue at general meetings, including the election of individual Directors.

All resolutions put forward at general meetings will be voted on by poll pursuant to the Listing Rules and poll results will be posted on the websites of the Company and of the Stock Exchange after each general meeting.

Procedures for Shareholders to Convene Extraordinary General Meeting

Pursuant to Article 12.3 of the Company's Articles of Association, general meetings shall be convened on the written requisition of any one or more members holding together, as at the date of deposit of the requisition, shares representing not less than one-tenth of the voting rights, on a one vote per share basis, of the Company which carry the right of voting at general meetings of the Company. The written requisition shall be deposited at the principal office of the Company in Hong Kong or, in the event the Company ceases to have such a principal office, the registered office of the Company, specifying the objects of the meeting and the resolutions to be added to the meeting agenda, and signed by the requisitioner(s).

7. GOVERNANCE ASPECT

If the Board does not within 21 days from the date of deposit of the requisition proceed duly to convene the meeting to be held within a further 21 days, the requisitionist(s) themselves or any of them representing more than one-half of the total voting rights of all of them, may convene the general meeting in the same manner, as nearly as possible, as that in which meetings may be convened by the Board provided that any meeting so convened shall not be held after the expiration of three months from the date of deposit of the requisition, and all reasonable expenses incurred by the requisitionist(s) as a result of the failure of the Board shall be reimbursed to them by the Company.

Putting Forward Proposals at General Meetings

There are no provisions in the Company's Articles of Association or in the Companies Law of the Cayman Islands for putting forward proposals of new resolutions by Shareholders at general meetings. Shareholders who wish to move forward a resolution may request the Company to convene a general meeting in accordance with the procedures mentioned above.

Detailed procedures for Shareholders to propose a person for election as a Director are published on the Company's website.

Putting forward enquiries to the Board

For putting forward any enquiries to the Board, Shareholders may send written enquiries to the Company. The Company will not normally deal with verbal or anonymous enquiries.

Shareholders may send their enquiries or requests as mentioned above to the following:

Address : Rooms 401, 403 and 405(A), 4/F
No. 998 Wenyi West Road (Haichuang Yuan)
Wuchang Street, Yuhang District, Hangzhou
Zhejiang Province, China

Email : cloudrir@91jkys.com

For the avoidance of doubt, Shareholder(s) must deposit and send the original duly signed written requisition, notice or statement, or enquiry (as the case may be) to the above address and provide their full name, contact details and identification in order to give effect thereto. The information of the Shareholder(s) may be disclosed as required by law.



Appendix: CONTENT INDEX FOR REPORTING GUIDE

Environmental, Social and Governance Reporting Guide		Report content
A: Environmental		
A1 Emissions		
General disclosure	Information on: (a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to air and greenhouse gas emissions, discharges into water and land, and generation of hazardous and non-hazardous waste.	Environmental Aspect — Overview
A1.1	The types of emissions and respective emissions data.	Overview; Green operation
A1.2	Direct (Scope 1) and energy indirect (Scope 2) greenhouse gas emissions and intensity.	Green operation
A1.3	Total hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Medical wastes management
A1.4	Total non-hazardous waste produced (in tonnes) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Medical wastes management
A1.5	Description of emission target(s) set and steps taken to achieve them.	Green operation
A1.6	Description of how hazardous and non-hazardous wastes are handled, and a description of reduction target(s) set and steps taken to achieve them.	Medical wastes management
A2 Use of Resources		
General Disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	Green operation
A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (kWh in '000s) and intensity (e.g. per unit of production volume, per facility).	Green operation
A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	Green operation
A2.3	Description of energy use efficiency target(s) set and steps taken to achieve them.	Green operation
A2.4	Description of whether there is any issue in sourcing water that is fit for purpose, water efficiency target(s) set and steps taken to achieve them.	Environmental Aspect — Overview
A2.5	Total packaging material used for finished products (in tonnes) and, if applicable, with reference to per unit produced.	Environmental Aspect — Overview
A3 The Environment and Natural Resources		
General Disclosure	Policies on minimising the issuer's significant impacts on the environment and natural resources.	Environmental Aspect — Overview
A3.1	Description of the significant impacts of activities on the environment and natural resources and the actions taken to manage them.	Environmental Aspect — Overview
A4 Climate Change		
General Disclosure	Policies on identification and mitigation of significant climate-related issues which have impacted, and those which may impact, the issuer.	Environmental Aspect — Overview
A4.1	Description of the significant climate-related issues which have impacted, and those which may impact, the issuer, and the actions taken to manage them.	Environmental Aspect — Overview

Appendix: CONTENT INDEX FOR REPORTING GUIDE



Environmental, Social and Governance Reporting Guide		Report content
B: Social		
B1 Employment		
General	(a) the policies; and	Employment and labor standard
Disclosure	(b) compliance with relevant laws and regulations that have a significant impact on the issuer.	
B1.1	Total workforce by gender, employment type (for example, full-or part-time), age group and geographical region.	Employment and labor standard
B1.2	Employee turnover rate by gender, age group and geographical region.	Employment and labor standard
B2 Health and Safety		
General	Information on:	Health and safety
Disclosure	(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to providing a safe working environment and protecting employees from occupational hazards.	
B2.1	Number and rate of work-related fatalities occurred in each of the past three years including the reporting year.	Health and safety
B2.2	Lost days due to work injury.	Health and safety
B2.3	Description of occupational health and safety measures adopted, and how they are implemented and monitored.	Health and safety
B3 Development and Training		
General	Policies on improving employees' knowledge and skills for discharging duties at work. Description of training activities.	Talent development and training
Disclosure		
B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management).	Talent development and training
B3.2	The average training hours completed per employee by gender and employee category.	Talent development and training



Appendix: CONTENT INDEX FOR REPORTING GUIDE

Environmental, Social and Governance Reporting Guide		Report content
B4 Labour Standards		
General	Information on:	Employment and labor standard; Employee recruitment and management provisions
Disclosure	(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to preventing child and forced labour.	Employment and labor standard; Employee recruitment and management provisions
B4.1	Description of measures to review employment practices to avoid child and forced labour.	Employment and labor standard; Employee recruitment and management provisions
B4.2	Description of steps taken to eliminate such practices when discovered.	Employment and labor standard; Employee recruitment and management provisions
Operating Practices		
B5 Supply Chain Management		
General	Policies on managing environmental and social risks of the supply chain.	Supply chain management
Disclosure		
B5.1	Number of suppliers by geographical region.	Supply chain management
B5.2	Description of practices relating to engaging suppliers, number of suppliers where the practices are being implemented, and how they are implemented and monitored.	Supply chain management
B5.3	Description of practices used to identify environmental and social risks along the supply chain, and how they are implemented and monitored.	Supply chain management
B5.4	Description of practices used to promote environmentally preferable products and services when selecting suppliers, and how they are implemented and monitored.	Supply chain management
B6 Product Responsibility		
General	Information on:	Product responsibility
Disclosure	(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to health and safety, advertising, labelling and privacy matters relating to products and services provided and methods of redress.	
B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Product responsibility
B6.2	Number of products and service related complaints received and how they are dealt with.	Product responsibility
B6.3	Description of practices relating to observing and protecting intellectual property rights.	Intellectual Property Management
B6.4	Description of quality assurance process and recall procedures.	Product responsibility
B6.5	Description of consumer data protection and privacy policies, how they are implemented and monitored.	Product responsibility

Appendix: CONTENT INDEX FOR REPORTING GUIDE



Environmental, Social and Governance Reporting Guide		Report content
B7 Anti-corruption		
General	Information on:	Anti-corruption
Disclosure	(a) the policies; and (b) compliance with relevant laws and regulations that have a significant impact on the issuer relating to bribery, extortion, fraud and money laundering.	
B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the Reporting Period and the outcomes of the cases.	Anti-corruption
B7.2	Description of preventive measures and whistle-blowing procedures, how they are implemented and monitored.	Anti-corruption
B7.3	Description of anti-corruption training provided to directors and staff.	Anti-corruption
B8 Community Investment		
General	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its activities take into consideration the communities' interests.	Community investment and participation
Disclosure		
B8.1	Focus areas of contribution (e.g. education, environmental concerns, labour needs, health, culture, sport).	Community investment and participation
B8.2	Resources contributed (e.g. money or time) to the focus area.	Community investment and participation

